Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death

被引：1
作者：
Friedrich, Jan O.
Adhikari, Neill K. J.
Meade, Maureen O.
机构：
[1] Univ Toronto, St Michaels Hosp, Crit Care Dept, Interdept Div Crit Care, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Interdept Div Crit Care, Toronto, ON M4N 3M5, Canada
[3] McMaster Univ, Dept Med, Dept Crit Care, Hamilton, ON L8N 3Z5, Canada
[4] McMaster Univ, Dept Clin Epidemiol & Biostat, Dept Crit Care, Hamilton, ON L8N 3Z5, Canada
来源：
CRITICAL CARE | 2006年 / 10卷 / 06期
关键词：
Random Effect; Severe Sepsis; Health Evaluation; Fixed Effect Model; Methodologic Difference;
D O I：
10.1186/cc5117
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：1
相关论文
共 7 条
[1]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[2]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[3]  
Egger M., 2001, Systematic Reviews in Health Care, V2nd ed.
[4]   Drotrecogin alfa (activated): down and not out, but not really in either [J].
Friedrich, Jan O. ;
Adhikari, Neill K. J. ;
Meade, Maureen O. .
CRITICAL CARE, 2006, 10 (05)
[5]   Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? [J].
Friedrich, Jan O. ;
Adhikari, Neill K. J. ;
Meade, Maureen O. .
CRITICAL CARE, 2006, 10 (03)
[6]   Measuring inconsistency in meta-analyses [J].
Higgins, JPT ;
Thompson, SG ;
Deeks, JJ ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560
[7]   Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death [J].
Williams, Mark D. ;
Janes, Jonathan M. ;
Nelson, David R. .
CRITICAL CARE, 2006, 10 (05)
1